HEALTH OF WOMAN. 2017.1(117):25–30

Веропотвелян П. Н., Радченко В. В., Цехмистренко И. С., Русак Н. С., Гнилуша И. С.
«Межобластной центр медицинской генетики и пренатальной диагностики», г. Кривой Рог
ФПО «Днепропетровская медицинская академия», г. Кривой Рог
Перинатальный центр, г. Киев
КДЦ КУ «Криворожский городской клинический родильный дом № 1» ДОС»

В статье проведен обзор литературы по прогностическим факторам развития преэклампсии (ПЭ) и эндотелиальной дисфункции в материнском кровотоке. Обращает на себя внимание одна из последних работ о прогнозировании ПЭ в течение 1 нед, а также риска развития данной патологии в течение 4 нед (исследование PROGNOSIS) на основании определения порогового значения отношения sFlt-1/PlGF. Пороговая точка отношения sFlt-1/PlGF, равная 38, имеет важное прогностическое значение. Значение sFlt-1/PlGF, равное 38 или ниже, имело отрицательное прогностическое значение в 99,3%, а выше 38 приводило к развитию ПЭ в течение 4 нед в 36,7% случаев. Отношение растворимой fms-подобной тирозинкиназы-1 к плацентарному фактору роста можно считать неинвазивным прогностическим маркером развития ПЭ.

Ключевые слова: преэклампсия, растворимая fms-подобная тирозинкиназа-1, плацентарный фактор роста, ангиогенез.

Литература:

1. Akolekar R., Syngelaki A., Sarquis R., ZvancaM., Nicolaides K.H. Prediction of early, intermediate and late pre-eclampsia from ma temal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 1: 66–74. https://doi.org/10.1002/pd.2660; PMid:21210481

2. Anderson U.D., Olsson M.G., Kristensen K.H., Вkerstmm B., Hansson S.R. Review: Biochemical markers to predict preeclampsia. Placenta 2012; 33: Suppl: 42–47.

3. Бlvarez-Fernбndez I., Prieto B., Rodrнguez V., Ruano Y., Escudero A.I., Бlvarez F.V. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin. Chem. Lab. Med. 2014; 52(8): 1159–68. https://doi.org/10.1515/cclm-2013-0901; PMid:24516004

4. Audibert E, Boucoiran I., An N., Aleksandrov N., Delvin E., Bujold E., Rey E. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynec 2010; 203:4: 383.el-8.

5. Benzing Т. Hypertension: Testing for pre-eclampsia: paving the way to early diagnosis. Nature Reviews Nephrology 02.2016.

6. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The «Great Obstetrical Syndromes» are associated with disorders of deep placentation. Am J Obstet Gynec 2011; 204: 3: 193–201. https://doi.org/10.1016/j.ajog.2010.08.009; PMid:21094932 PMCid:PMC3369813

7. Chappell L.C., Duckworth S., Seed P.T., Griffin M., Myers J., Mackillop L. et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013; 128(19): 2121–31. https://doi.org/10.1161/circulationaha.113.003215

8. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia. Part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 2014; 10: 466–80. https://doi.org/10.1038/nrneph.2014.102; PMid:25003615

9. Chaiworapongsa T., Romero R., Kim Y.M. et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18. https://doi.org/10.1080/14767050400028816; PMid:15804781

10. Cnossen J.S., Morris R.K., ter Riet G., Mol B. W., van der Post J.A., Coomarasamy A., Zwinderman A.H., Robson S.C., Bindels P.J., Kleijnen J.,  Khan K.S. Use of uterine artery Doppler ultrasonogra phy to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 6: 701–711. https://doi.org/10.1503/cmaj.070430; PMid:18332385 PMCid:PMC2263112

11. De Vivo A., Baviera G., Giordano D., Todarello G., Corrado E, Anna R. Endoglin, P1GF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynec Scand 2008; 87: 8: 837–842. https://doi.org/10.1080/00016340802253759; PMid:18607829

12. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N., Gerber H.P., Kikkawa Y., Miner J.H., Quaggin S.E. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 5: 707–716. https://doi.org/10.1172/JCI17423; PMid:12618525 PMCid:PMC151905

13. Grill S., Rusterholz C., Zanetti-Dдllenbach R. et al. Potential markers of preeclampsia — a review. J Reprod Biol Endocrinol 2009; 7: 70. https://doi.org/10.1186/1477-7827-7-70; PMid:19602262 PMCid:PMC2717076

14. Holmes V.A., Young I.S., Patterson C.C., Maresh M.J., Pearson D.W., Walker J.D., McCance D.R.; Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013; 36(11): 3671–7. https://doi.org/10.2337/dc13-0944; PMid:23920083 PMCid:PMC3816852

15. Husse S., Gottschlich A., Schrey S., Stepan H., Hoffmann J. Predictive value of the sFlt1/PlGF ratio for the diagnosis of preeclampsia in high-risk patients. Z. Geburtshilfe Neonatol. 2014; 218(1): 34–41. PMid:24595913

16. Kusanovic J.P., Romero R., Chaiworapongsa T., Erez O., Mittal P., Vaisbuch E. et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 2009; 22(11): 1021–38. https://doi.org/10.3109/14767050902994754; PMid:19900040 PMCid:PMC3427777

17. Kvehaugen A.S., Dechend R., Ramstad H.B., Troisi R., Fugelseth D., Staff A.C. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 2011; 58(1): 63–9. https://doi.org/10.1161/HYPERTENSIONAHA.111.172387; PMid:21606387

18. Lai J., Garcia-Tizon Larroca S., Peeva G., Poon L.C., Wright D., Nicolaides K.H. Competing risks model in screening for pre-eclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn. Ther. 2014; 35(4): 240–8. https://doi.org/10.1159/000359968; PMid:24853452

19. Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol. 2012; 64(4): 309-20. PMid:22728575 PMCid:PMC3796355

20. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350(7): 672–83. https://doi.org/10.1056/NEJMoa031884; PMid:14764923

21. Maharaj A.S., Walshe T.E., Saint-Geniez M., Venkatesha S., Maldonado A.E., Himes N.C., Matharu K.S., Karumanchi S.A. D’Amore P.A. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008; 205:2: 491–501. https://doi.org/10.1084/jem.20072041; PMid:18268040 PMCid:PMC2271023

22. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649–58. https://doi.org/10.1172/jci17189

23. Moore Simas T.A., Crawford S.L., Solitro M.J., Frost S.C., Meyer B.A., Maynard S.E. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 2007; 197(3): 244. e1–8.

24. Myers J.E., Kenny L.C., McCowan L.M., Chan E.H., Dekker G.A.,Poston L., Simpson N.A., North R.A. SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm preeclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013; 120: 10:1215–1223. https://doi.org/10.1111/1471-0528.12195; PMid:23906160

25. OdiboA.O., Zhong Y., Goetzinger K.R., Odibo L., BickJ.L., Bower C.R., Nelson D.M. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of preeclampsia. Placenta 2011; 32: 8: 598–602. https://doi.org/10.1016/j.placenta.2011.05.006; PMid:21652068 PMCid:PMC3142303

26. Olsson M.G., Olofsson T, Tapper H., Akerstrom B. The lipocalin alpha1-microglobulin protects erythroid K562 cells against oxidative damage induced by heme and reactive oxygen species. Free Radie Res 2008; 42: 8: 725–736. https://doi.org/10.1080/10715760802337265; PMid:18712632

27. Polsani S., Phipps E., Jim B. Emerging new biomarkers of preeclampsia. Adv. Chronic Kidney Dis. 2013; 20(3): 271–9. https://doi.org/10.1053/j.ackd.2013.01.001; PMid:23928393

28. Rana S., Karumanchi S.A., Levine R.J., Venkatesha S., Rauh-Hain J.A., Tamez H., Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007; 50(1): 137–42. https://doi.org/10.1161/HYPERTENSIONAHA.107.087700; PMid:17515455

29. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012; 125(7): 911–9. https://doi.org/10.1161/CIRCULATIONAHA.111.054361; PMid:22261192 PMCid:PMC3319742

30. Reddy A., Suri S., Sargent I.L., Redman C.W., Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One. 2009; 4(2): e4453. https://doi.org/10.1371/journal.pone.0004453; PMid:19412349 PMCid:PMC2675175

31. Sбnchez-Aranguren L.С. et all. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front. Physiol., 10 October 2014.

32. Serov V.N., Kan N.E., Tyutyunik V.L. Prognosticvalue of ratio of soluble fms-like tyrokinase-1 to placental growth factor in pregnant women with preeclampsia //Obstetrics and Gynecology. 2016; 6:5–10.

33. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet. 2005; 365 (9461): 785–99. https://doi.org/10.1016/S0140-6736(05)71003-5

34. Sidorova I. S., Nikitina N.A. Predictive, preventive approach to the management of pregnancies at risk of pre-eclampsia //Russian vestnik Obstetrics and Gynecology. 2014; 5(14): 44–49.

35. Staff A.C. Circulating predictive biomarkers in preeclampsia. Pregnancy Hypertens. 2011; 1(1): 28–42. https://doi.org/10.1016/j.preghy.2010.10.012

36. Staff A.C., Benton S.J., von Dadelszen P., Roberts J.M., Taylor R.N., Powers R.W. et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013; 61(5): 932–42. https://doi.org/10.1161/HYPERTENSIONAHA.111.00250; PMid:23460278

37. Staff A.C., Braekke K., Harsem N.K., Lyberg T., Holthe M.R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 122(1): 33–9. https://doi.org/10.1016/j.ejogrb.2004.11.015; PMid:15935542

38. Stepan H., Geipel A., Schwarz F., Krдmer T., Wessel N., Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol. 2008; 198(2): 175. e1-6.

39. Thadhani R., Mutter W.P., Wolf M. et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770–775. https://doi.org/10.1210/jc.2003-031244; PMid:14764795

40. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., Staff A.C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am. J. Obstet. Gynecol. 2007; 196(3): 239–46. https://doi.org/10.1016/j.ajog.2006.10.909; Mid:17346536

41. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014; 63(2): 346–52. https://doi.org/10.1161/HYPERTENSIONAHA.113.01787; PMid:24166751

42. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G., Pape J., Dudenhausen J. W., Denk B., Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202: 2:161.el-161.ell.

43. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010; 202(2): 161. e1-161. e11.

 44. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Moertl M., Zeisler H. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am. J. Obstet. Gynecol. 2012; 206(1): 58. e1-8.

45. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014; 63(2): 346–52. https://doi.org/10.1161/HYPERTENSIONAHA.113.01787; PMid:24166751

46. Villa P.M., Hдmдlдinen E., Mдki A., Rдikkцnen K., Pesonen A.K., Taipale P. et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth. 2013; 13: 110. https://doi.org/10.1186/1471-2393-13-110; PMid:23663420 PMCid:PMC3661359

47. Wathen K.A., Tuutti E., Stenmun U.H., Alfthan H., Halmesmaki E., Finne P, Ylikorkala O., Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J. Clin Endocrinol Metabol. 2006; 91: 1: 180–184. https://doi.org/10.1210/jc.2005-1076; PMid:16263826

48. Wikstrцm A.K., Larsson A., Eriksson U.J., Nash P., Nordйn-Lindeberg S., Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007; 109(6): 1368–74. https://doi.org/10.1097/01.AOG.0000264552.85436.a1; PMid:17540809

49. Wortelboer E.J., KosterM.P., Cuckle H.S., Stoutenbeek P.H.,  Schielen P.C., Visser G.H. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG 2010; 117: 11: 1384–1389. https://doi.org/10.1111/j.1471-0528.2010.02690.x; PMid:20840693

50. Xu Q.S., Liang Y.Z., Du Y.P. Monte Carlo cross-validation for selecting a model and estimating the prediction error in multivariate calibration. J. Chemometrics. 2004; 18(2): 112–20. https://doi.org/10.1002/cem.858

51. Young В. C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Annu Rev Pathol 2010; 5: 173–192. https://doi.org/10.1146/annurev-pathol-121808-102149; PMid:20078220

52. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A.C., Sennstrцm M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13–22. https://doi.org/10.1056/NEJMoa1414838; PMid:26735990

53. Zhang J., Klebanoff M.A., Roberts J.M. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet. Gynecol. 2001; 97(2): 261–7. https://doi.org/10.1016/S0029-7844(00)01125-X; https://doi.org/10.1097/00006250-200102000-00018